Androgenetic alopecia (AGA) is currently the primary cause of hair loss in both men and women. It is characterized by a progressive thinning of the hair follicles due to a shortening of the anagen phase of the hair growth cycle. The pathophysiology mainly involves the accumulation of dihydrotestosterone (DHT), a metabolite of testosterone, and a chronic perifollicular inflammatory process. The objective of this study is to evaluate, through a literature review, the validity, protocols, and efficacy of the use of platelet-rich plasma (PRP) in the treatment of patients with AGA. It is a review conducted in the first half of 2024, using the PubMed and BVS databases, employing Descritores em Ciência e Saúde (alopecia, plasma rico em plaquetas, terapia) and Medical Subject Headings (alopecia, platelet-rich plasma, therapy). Inclusion criteria consisted of: a) articles published between 2022 and 2024; b) written in Portuguese or English; c) full-text articles available for free; d) research focused on PRP therapy for the treatment of androgenetic alopecia in men. Twelve articles were included in the synthesis. Overall, the articles indicated that despite the need for standardized protocols, the use of PRP as a treatment for AGA shows promising results in the current context. The therapy demonstrated improvements in hair density and patient satisfaction, suggesting its potential as a viable option for managing androgenetic alopecia. Besides being a safe option with minimal side effects, its combination with other therapies, such as minoxidil, has brought beneficial outcomes for patients with this condition. Keywords: Alopecia, Platelet-Rich Plasma, Therapy
Read full abstract